Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Ottawa Hospital Research Institute
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Jun 7, 2023
Discovery & Translation
Rare variants predict risk of common disease severity
BioCentury’s roundup of translational news
BioCentury | May 17, 2023
Regulation
May 17 Quick Takes: Intercept falls on negative tone of FDA briefing docs
Plus: Siren, Sania debut and updates from Aitia, PTC, enGene, Ardelyx, Akero and Satellos
BioCentury | Jun 2, 2022
Distillery Therapeutics
Oncolytic virus expressing an ARID1A inhibitor for cancer
BioCentury | Feb 29, 2016
Product Development
Infectious enthusiasm
How oncolytic viruses are coming of age in cancer immunotherapy combinations
BioCentury | Feb 22, 2016
Emerging Company Profile
Oncolytic immunotherapy
How Turnstone is combining an oncolytic virus with cancer vaccines
BioCentury | Jan 21, 2016
Targets & Mechanisms
Snipping vs. skipping for DMD
Why CRISPR might be better than exon skipping for DMD
Items per page:
1 - 10 of 16